Rethymic
smartbax licenses compound from Aicuris for next-generation antibiotic development
The new programme addresses the urgent unmet medical need for new therapies to tackle antibiotic-resistant infections
BMS and Bain Capital launch new company to develop immunology therapies
The newly formed company has in-licensed five investigational immunology drugs from BMS
AbbVie to expand immunology capabilities with $2.1bn Capstan acquisition
The deal includes a CAR-T therapy in phase 1 development for B cell-mediated autoimmune diseases
Sanofi to expand immunology capabilities with $9.5bn Blueprint acquisition
The deal will grant Sanofi access to a drug approved for the rare immunologic disorder systemic mastocytosis
AbbVie and ADARx enter multi-billion dollar partnership to develop siRNA therapies
The companies will focus on developing therapeutics across neuroscience, immunology and oncology
Sanofi expands immunology pipeline by acquiring Dren’s bispecific for $600m upfront
The candidate has shown potential in treating B-cell mediated autoimmune diseases
AbbVie and Neomorph enter molecular glue degrader partnership worth $1.64bn
The companies are aiming to develop MGDs for targets across oncology and immunology
AbbVie to expand immunology pipeline with $200m Nimble Therapeutics acquisition
The deal includes an IL23R inhibitor in preclinical development for psoriasis and inflammatory bowel disease
Novartis and Schrödinger to advance drug candidates in deal worth over $2.4bn
The companies will advance therapeutics for undisclosed targets in Novartis’ core areas
GSK expands immunology pipeline by acquiring Chimagen’s CMG1A46 in deal worth $850m
The company plans to develop the candidate for autoimmune diseases such as lupus
GSK and Flagship Pioneering partner in deal worth up to $7bn to discover medicines and vaccines
The companies aim to develop a portfolio of up to ten candidates
Sanofi and Belharra Therapeutics enter $700m immunological disease collaboration
The partnership will utilise Belharra’s platform to identify and advance small molecules against immunology targets